Pier Mannuccio Mannucci

List of Publications by Year
in descending order

323 papers	18,066 citations	14655 66 h-index	15732 125 g-index

329 all docs	329 docs citations	329 times ranked	13763 citing authors

#	Article	IF	Citations
1	The Coagulopathy of Chronic Liver Disease. New England Journal of Medicine, 2011, 365, 147-156.	27.0	1,171
2	Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. Journal of Thrombosis and Haemostasis, 2006, 4, 2103-2114.	3.8	1,061
3	The Hemophilias â€" From Royal Genes to Gene Therapy. New England Journal of Medicine, 2001, 344, 1773-1779.	27.0	936
4	Hemostatic Drugs. New England Journal of Medicine, 1998, 339, 245-253.	27.0	581
5	Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood, 2001, 98, 2730-2735.	1.4	488
6	Recessively inherited coagulation disorders. Blood, 2004, 104, 1243-1252.	1.4	479
7	Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years. Blood, 1997, 90, 2515-2521.	1.4	466
8	Treatment of von Willebrand's Disease. New England Journal of Medicine, 2004, 351, 683-694.	27.0	464
9	Prevention and Treatment of Major Blood Loss. New England Journal of Medicine, 2007, 356, 2301-2311.	27.0	445
10	A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). Journal of Thrombosis and Haemostasis, 2011, 9, 700-710.	3.8	390
11	Different Risks of Thrombosis in Four Coagulation Defects Associated With Inherited Thrombophilia: A Study of 150 Families. Blood, 1998, 92, 2353-2358.	1.4	378
12	Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood, 2003, 102, 2358-2363.	1.4	351
13	Health Effects of Ambient Air Pollution in Developing Countries. International Journal of Environmental Research and Public Health, 2017, 14, 1048.	2.6	319
14	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	288
15	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106, 1262-1267.	1.4	275
16	Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. European Journal of Clinical Pharmacology, 2011, 67, 507-519.	1.9	255
17	Effects on health of air pollution: a narrative review. Internal and Emergency Medicine, 2015, 10, 657-662.	2.0	200
18	SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta. EBioMedicine, 2020, 59, 102951.	6.1	193

#	Article	IF	Citations
19	Multiple Diseases and Polypharmacy in the Elderly: Challenges for the Internist of the Third Millennium. Journal of Comorbidity, 2011, 1, 28-44.	3.9	192
20	TRANSMISSION OF NON-A, NON-B HEPATITIS BY HEAT-TREATED FACTOR VIII CONCENTRATE. Lancet, The, 1985, 326, 1-4.	13.7	188
21	Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). British Journal of Haematology, 1992, 82, 87-93.	2.5	169
22	Thrombogenicity and cardiovascular effects of ambient air pollution. Blood, 2011, 118, 2405-2412.	1.4	167
23	A Common Mutation in the Methylenetetrahydrofolate Reductase Gene (C677T) Increases the Risk for Deep-Vein Thrombosis in Patients With Mutant Factor V (Factor V:Q 506). Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1662-1666.	2.4	161
24	How I treat patients with von Willebrand disease. Blood, 2001, 97, 1915-1919.	1.4	157
25	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2014, 61, 148-154.	3.7	149
26	Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale. Drugs and Aging, 2013, 30, 103-112.	2.7	140
27	Back to the future: a recent history of haemophilia treatment. Haemophilia, 2008, 14, 10-18.	2.1	137
28	Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. British Journal of Haematology, 1995, 91, 434-444.	2.5	134
29	Hemophilia therapy: the future has begun. Haematologica, 2020, 105, 545-553.	3.5	132
30	The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood, 2014, 123, 4037-4044.	1.4	123
31	Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. Journal of Thrombosis and Haemostasis, 2009, 7, 780-786.	3.8	122
32	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Internal and Emergency Medicine, 2014, 9, 723-734.	2.0	121
33	Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood, 2013, 122, 648-657.	1.4	120
34	von Willebrand factor/factor VIII concentrate (HaemateÂ® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. Journal of Thrombosis and Haemostasis, 2007, 5, 1420-1430.	3.8	118
35	Shortâ€term effects of air pollution on cardiovascular diseases: outcomes and mechanisms. Journal of Thrombosis and Haemostasis, 2007, 5, 2169-2174.	3.8	115
36	Treatment of severe von Willebrand disease with a highâ€purity von Willebrand factor concentrate (WilfactinÂ®): a prospective study of 50 patients. Journal of Thrombosis and Haemostasis, 2007, 5, 1115-1124.	3.8	111

#	Article	IF	Citations
37	Impact on human health of climate changes. European Journal of Internal Medicine, 2015, 26, 1-5.	2.2	107
38	Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia, 2000, 6, 60-67.	2.1	104
39	FactorÂVIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophiliaAA patients with highâ€responding inhibitors. Journal of Thrombosis and Haemostasis, 2009, 7, 1809-1815.	3.8	103
40	Acquired haemophilia A: A 2013 update. Thrombosis and Haemostasis, 2013, 110, 1114-1120.	3.4	103
41	Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. British Journal of Haematology, 2004, 126, 213-218.	2.5	99
42	Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia, 2013, 19, 76-81.	2.1	99
43	Classic thrombophilic gene variants. Thrombosis and Haemostasis, 2015, 114, 885-889.	3.4	93
44	Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. Haemophilia, 1997, 3, 242-246.	2.1	92
45	ABSENCE OF ANTIBODIES TO AIDS VIRUS IN HAEMOPHILIACS TREATED WITH HEAT-TREATED FACTOR VIII CONCENTRATE. Lancet, The, 1985, 325, 271-272.	13.7	91
46	Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. British Journal of Haematology, 2000, 111, 1236-1239.	2.5	91
47	Air pollution and cardiovascular disease. Thrombosis Research, 2012, 129, 230-234.	1.7	91
48	Biochemical and Metabolic Aspects of Platelet Dysfunction in Chronic Myeloproliferative Disorders. Thrombosis and Haemostasis, 1982, 47, 084-089.	3.4	91
49	Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	2.1	90
50	Coâ€morbidities and quality of life in elderly persons with haemophilia. British Journal of Haematology, 2010, 148, 522-533.	2.5	90
51	The Effect of Desmopressin on Reducing Blood Loss in Cardiac Surgery â€“ A Meta-Analysis of Double-Blind, Placebo-Controlled Trials. Thrombosis and Haemostasis, 1995, 74, 1064-1070.	3.4	89
52	Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia, 2008, 14, 444-453.	2.1	88
53	Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia, 2012, 18, e173-87.	2.1	88
54	Novel evidence for a greater burden of ambient air pollution on cardiovascular disease. Haematologica, 2019, 104, 2349-2357.	3.5	88

#	Article	IF	Citations
55	Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood, 1997, 90, 2515-21.	1.4	88
56	Clinical use of Haemate(R) P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. Haematologica, 2007, 92, 944-951.	3.5	85
57	Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica, 2003, 88, 914-8.	3.5	85
58	Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. Journal of Thrombosis and Haemostasis, 2006, 4, 721-723.	3.8	82
59	Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia, 2007, 13, 373-379.	2.1	81
60	Deficiency of (33P)2MeS-ADP Binding Sites on Platelets with Secretion Defect, Normal Granule Stores and Normal Thromboxane A2 Production. Thrombosis and Haemostasis, 1997, 77, 0986-0990.	3.4	76
61	Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study. European Journal of Internal Medicine, 2014, 25, 617-623.	2.2	75
62	How we choose factor VIII to treat hemophilia. Blood, 2012, 119, 4108-4114.	1.4	74
63	Clinical Evaluation of Viral Safety of Coagulation Factor VIII and IX Concentrates. Vox Sanguinis, 1993, 64, 197-203.	1.5	73
64	Intravenous and Subcutaneous Administration of Desmopresssin (DDAVP) to Hemophiliacs: Pharmacokinetics and Factor VIII Responses. Thrombosis and Haemostasis, 1987, 58, 1037-1039.	3.4	69
65	Von Willebrand diseaseâ€associated angiodysplasia: a few answers, still many questions. British Journal of Haematology, 2013, 161, 177-182.	2.5	68
66	Acquired von Willebrand syndrome: focused for hematologists. Haematologica, 2020, 105, 2032-2037.	3.5	67
67	Laboratory Screening of Inherited Thrombotic Syndromes. Thrombosis and Haemostasis, 1987, 57, 247-251.	3.4	67
68	Under-detection of delirium and impact of neurocognitive deficits on in-hospital mortality among acute geriatric and medical wards. European Journal of Internal Medicine, 2015, 26, 696-704.	2.2	65
69	Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfusion, 2009, 7, 117-26.	0.4	63
70	Is haemophilia B less severe than haemophilia A?. Haemophilia, 2013, 19, 499-502.	2.1	61
71	Pharmacokinetics of Monoclonally-Purified and Recombinant Factor VIII in Patients with Severe von Willebrand Disease. Thrombosis and Haemostasis, 1993, 70, 270-272.	3.4	60
72	Gastrointestinal angiodysplasia and bleeding in von Willebrand disease. Thrombosis and Haemostasis, 2014, 112, 427-431.	3.4	60

#	Article	IF	Citations
73	Hemostasis Abnormalities in Patients with Vascular Dementia and Alzheimerâ€™s Disease. Thrombosis and Haemostasis, 1996, 75, 216-218.	3.4	60
74	Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. American Journal of Hematology, 1989, 31, 32-35.	4.1	59
75	Prevalence of potentially inappropriate medications and risk of adverse clinical outcome in a cohort of hospitalized elderly patients: results from the REPOSI Study. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 511-515.	1.5	59
76	Mitigation of air pollution by greenness: A narrative review. European Journal of Internal Medicine, 2018, 55, 1-5.	2.2	55
77	Drugâ€“drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiology and Drug Safety, 2013, 22, 1054-1060.	1.9	53
78	Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfusion, 2019, 17, 479-486.	0.4	53
79	Inhibitor eradication with rituximab in haemophilia: where do we stand?. British Journal of Haematology, 2014, 165, 600-608.	2.5	51
80	COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis. Diagnostics, 2021, 11, 955.	2.6	49
81	Risk of thromboembolic complications in patients with inflammatory bowel disease. International Journal of Clinical and Laboratory Research, 1992, 21, 165-170.	1.0	48
82	Old and new anticoagulant drugs: A minireview. Annals of Medicine, 2011, 43, 116-123.	3.8	48
83	Hemostatic defects in liver and renal dysfunction. Hematology American Society of Hematology Education Program, 2012, 2012, 168-173.	2.5	48
84	Post-mortem findings in vaccine-induced thrombotic thombocytopenia. Haematologica, 2021, 106, 2291-2293.	3.5	47
85	Adverse Effects of Treatment with Porcine Factor VIII. Thrombosis and Haemostasis, 1991, 65, 245-247.	3.4	47
86	Polypharmacy in older people: lessons from 10Âyears of experience with the REPOSIÂregister. Internal and Emergency Medicine, 2018, 13, 1191-1200.	2.0	45
87	Subcutaneous Desmopressin (DDAVP) Shortens the Prolonged Bleeding Time in Patients with Liver Cirrhosis. Thrombosis and Haemostasis, 1990, 64, 358-360.	3.4	45
88	Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood, 2017, 130, 1757-1759.	1.4	44
89	Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease. Journal of the American Heart Association, 2016, 5, .	3.7	43
90	Association between particulate air pollution and venous thromboembolism: A systematic literature review. European Journal of Internal Medicine, 2016, 27, 10-13.	2.2	43

#	Article	IF	Citations
91	High Frequency of the C677T Mutation in the Methylenetetrahydrofolate Reductase (MTHFR) Gene in Northern Italy. Thrombosis and Haemostasis, 1997, 78, 963-964.	3.4	43
92	Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 72, glw188.	3.6	41
93	Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood, 2017, 129, 1245-1250.	1.4	41
94	Venous thromboembolism in von Willebrand disease. Thrombosis and Haemostasis, 2002, 88, 378-9.	3.4	41
95	Efficacy and safety of highly purified, doubly virusâ€inactivated VWF/FVIII concentrates in inherited von Willebrandâ€™s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score. Haemophilia, 2010, 16, 101-110.	2.1	39
96	Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica, 2003, 88, 454-8.	3.5	37
97	Familial Dysfunction of Protein S. Thrombosis and Haemostasis, 1989, 62, 763-766.	3.4	34
98	Comparison of Functional Assays for Protein S: European Collaborative Study of Patients with Congenital and Acquired Deficiency. Thrombosis and Haemostasis, 1993, 70, 0946-0950.	3.4	34
99	Fibrinogen Milano II: A Congenital Dysfibrinogenaemia Associated with Juvenile Arterial and Venous Thrombosis. Thrombosis and Haemostasis, 1986, 55, 131-135.	3.4	34
100	The International Society for Thrombosis and Haemostasis owns its official journal: the future has begun!. Journal of Thrombosis and Haemostasis, 2003, 1, 1-2.	3.8	33
101	Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement. Seminars in Thrombosis and Hemostasis, 2016, 42, 526-532.	2.7	32
102	Von Willebrand factor (VonvendiÂ®): the first recombinant product licensed for the treatment of von Willebrand disease. Expert Review of Hematology, 2016, 9, 825-830.	2.2	32
103	Uncertain thrombophilia markers. Thrombosis and Haemostasis, 2016, 115, 25-30.	3.4	32
104	Immune Status of Asymptomatic HIV-Infected Hemophiliacs: Randomized, Prospective, Two-Year Comparison of Treatment with a High-Purity or an Intermediate-Purity Factor VIII Concentrate. Thrombosis and Haemostasis, 1992, 67, 310-313.	3.4	32
105	Von Willebrand factor contaminating porcine factor VIII concentrate (Hyate: C) causes platelet aggregation. British Journal of Haematology, 1986, 63, 703-711.	2.5	31
106	Venous thrombosis and anticoagulant therapy. British Journal of Haematology, 2001, 114, 258-270.	2.5	31
107	Modern Treatment of Hemophilia: From the Shadows Towards the Light. Thrombosis and Haemostasis, 1993, 70, 017-023.	3.4	31
108	Treatment of von Willebrand disease. Haemophilia, 1998, 4, 661-664.	2.1	30

#	Article	IF	Citations
109	Antithrombin Milano, Single Amino Acid Substitution at the Reactive Site, Arg393 to Cys. Thrombosis and Haemostasis, 1988, 60, 471-475.	3.4	29
110	Healthâ€related quality of life and psychological wellâ€being in elderly patients with haemophilia. Haemophilia, 2012, 18, 345-352.	2.1	29
111	Half-life extension technologies for haemostatic agents. Thrombosis and Haemostasis, 2015, 113, 165-176.	3.4	29
112	New therapies for von Willebrand disease. Blood Advances, 2019, 3, 3481-3487.	5.2	29
113	Sustained correction of the bleeding time in an afibrinogenaemic patient after infusion of fresh frozen plasma. British Journal of Haematology, 1992, 82, 388-390.	2.5	28
114	Low Levels of the Anticoagulant Activity of Protein C in Patients with Chronic Renal Insufficiency: an Inhibitor of Protein C Is Present in Uremic Plasma. Thrombosis and Haemostasis, 1991, 66, 420-425.	3.4	28
115	Intramuscular antiâ€D immunoglobulins for home treatment of chronic immune thrombocytopenic purpura. British Journal of Haematology, 1992, 80, 337-340.	2.5	27
116	Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with allâ€transâ€retinoic acid. British Journal of Haematology, 1996, 92, 733-739.	2.5	27
117	The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. Thrombosis Research, 2015, 136, 851-854.	1.7	27
118	Direct oral anticoagulants and venous thromboembolism. European Respiratory Review, 2016, 25, 295-302.	7.1	27
119	SIPPET: methodology, analysis and generalizability. Haemophilia, 2017, 23, 353-361.	2.1	27
120	The never ending success story of tranexamic acid in acquired bleeding. Haematologica, 2020, 105, 1201-1205.	3.5	27
121	Potentially Inappropriate Medications, Drugâ€“Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes?. Drugs and Aging, 2020, 37, 585-593.	2.7	27
122	Type I von Willebrand disease, subtype â€˜platelet lowâ€™: decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells. British Journal of Haematology, 1993, 83, 88-93.	2.5	26
123	Progress in the contemporary management of hemophilia: The new issue of patient aging. European Journal of Internal Medicine, 2017, 43, 16-21.	2.2	26
124	Improving primary care in Europe beyond COVID-19: from telemedicine to organizational reforms. Internal and Emergency Medicine, 2021, 16, 255-258.	2.0	26
125	Antibody to Hepatitis G Mrus after a Vapour-Heated Factor Vlll Goncentrate. Thrombosis and Haemostasis, 1990, 64, 232-234.	3.4	26
126	Multicenter Comparison of Five Functional and Two Immunological Assays for Protein C. Thrombosis and Haemostasis, 1987, 57, 044-048.	3.4	26

#	Article	IF	Citations
127	Liver disease, coagulopathies and transfusion therapy. Blood Transfusion, 2013, 11, 32-6.	0.4	26
128	Gender difference in drug use in hospitalized elderly patients. European Journal of Internal Medicine, 2015, 26, 483-490.	2.2	25
129	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. European Journal of Internal Medicine, 2015, 26, 330-337.	2.2	25
130	Venous thrombosis: the history of knowledge. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2002, 32, 209-212.	0.3	24
131	AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. Journal of Thrombosis and Haemostasis, 2003, 1, 2065-2069.	3.8	24
132	The Health and Economic Burden of Air Pollution. American Journal of Medicine, 2015, 128, 931-932.	1.5	24
133	Drugâ€“drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. European Journal of Internal Medicine, 2019, 65, 51-57.	2.2	24
134	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget, 2016, 7, 80083-80090.	1.8	24
135	Red cells playing as activated platelets in thalassemia intermedia. Journal of Thrombosis and Haemostasis, 2010, 8, 2149-2151.	3.8	23
136	Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. Journal of Thrombosis and Haemostasis, 2018, 16, 778-790.	3.8	23
137	Noise and air pollution as triggers of hypertension. European Heart Journal, 2021, 42, 2085-2087.	2.2	23
138	Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clinical Advances in Hematology and Oncology, 2016, 14 Suppl 11, 2-15.	0.3	23
139	Prescription Drug Use Among Older Adults in Italy: A Country-Wide Perspective. Journal of the American Medical Directors Association, 2014, 15, 531.e11-531.e15.	2.5	22
140	Pain and Frailty in Hospitalized Older Adults. Pain and Therapy, 2020, 9, 727-740.	3.2	22
141	Ageing successfully with haemophilia: A multidisciplinary programme. Haemophilia, 2018, 24, 57-62.	2.1	21
142	Miracle of haemophilia drugs: Personal views about a few main players. Haemophilia, 2018, 24, 557-562.	2.1	21
143	Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register. Journal of Clinical Medicine, 2019, 8, 81.	2.4	21
144	Coexistence of a novel homozygous nonsense mutation in exon 13 of the factor V gene with the homozygous Leiden mutation in two unrelated patients with severe factor V deficiency. British Journal of Haematology, 2001, 114, 871-874.	2.5	20

#	Article	IF	Citations
145	Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia. Expert Opinion on Pharmacotherapy, 2012, 13, 505-510.	1.8	20
146	Oral Contraceptives Are a Risk Factor for Cerebral Vein Thrombosis. Thrombosis and Haemostasis, 1996, 76, 477-478.	3.4	20
147	Present and future challanges in the treatment of haemophilia: a clinician's perspective. Blood Transfusion, 2013, 11 Suppl 4, s77-81.	0.4	20
148	Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood, 1992, 79, 3130-7.	1.4	20
149	Resistance to activated protein C in unselected patients with arterial and venous thrombosis. American Journal of Hematology, 1997, 55, 59-64.	4.1	19
150	The real value of thrombophilia markers in identifying patients at high risk of venous thromboembolism. Expert Review of Hematology, 2014, 7, 757-765.	2.2	19
151	Disability, and not diabetes, is a strong predictor of mortality in oldest old patients hospitalized with pneumonia. European Journal of Internal Medicine, 2018, 54, 53-59.	2.2	19
152	The Effect of Instrumentation on Thromboplastin Calibration. Thrombosis and Haemostasis, 1992, 67, 588-589.	3.4	19
153	Type II H von willebrand disease: New structural abnormality of plasma and platelet von willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity. American Journal of Hematology, 1989, 32, 287-293.	4.1	18
154	Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor. British Journal of Haematology, 1994, 86, 333-337.	2.5	18
155	Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease. Haemophilia, 2017, 23, 182-187.	2.1	18
156	Primary hyperfibrinolysis: Facts and fancies. Thrombosis Research, 2018, 166, 71-75.	1.7	18
157	Comorbidity does not mean clinical complexity: evidence from the RePoSI register. Internal and Emergency Medicine, 2020, 15, 621-628.	2.0	18
158	Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry. Internal and Emergency Medicine, 2021, 16, 389-400.	2.0	18
159	Telemedicine and telerehabilitation: current and forthcoming applications in haemophilia. Blood Transfusion, 2019, 17, 385-390.	0.4	18
160	Novel investigations on the protective role of the <scp>FVIII</scp>/<scp>VWF</scp> complex in inhibitor development. Haemophilia, 2014, 20, 2-16.	2.1	17
161	Management of Bleeding Associated with New Oral Anticoagulants. Seminars in Thrombosis and Hemostasis, 2015, 41, 788-801.	2.7	17
162	Understanding organ dysfunction in thrombotic thrombocytopenic purpura. Intensive Care Medicine, 2015, 41, 715-718.	8.2	17

#	Article	IF	Citations
163	Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A. Journal of Thrombosis and Haemostasis, 2016, 14, 1330-1336.	3.8	17
164	Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients. Archives of Gerontology and Geriatrics, 2017, 69, 21-30.	3.0	17
165	Treatment of haemophilia: building on strength in the third millennium. Haemophilia, 2011, 17, 1-24.	2.1	16
166	Prognostic value of estimated glomerular filtration rate in hospitalized elderly patients. Internal and Emergency Medicine, 2014, 9, 735-747.	2.0	16
167	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. International Journal of Cardiology, 2017, 232, 98-104.	1.7	16
168	Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. European Journal of Internal Medicine, 2017, 46, 6-10.	2.2	16
169	Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. Expert Opinion on Investigational Drugs, 2020, 29, 303-309.	4.1	16
170	Human Platelet Aggregation and Release Reaction Induced by Platelet Activating Factor (PAF-Acether) â€“ Effects of Acetylsalicylic Acid and External Ionized Calcium. Thrombosis and Haemostasis, 1985, 53, 221-224.	3.4	16
171	Treatment of von Willebrand Disease. Hematology, 1998, 3, 339-346.	1.5	15
172	Air pollution levels and cardiovascular health: Low is not enough. European Journal of Preventive Cardiology, 2017, 24, 1851-1853.	1.8	15
173	Comorbidities in persons with haemophilia aged 60 years or more compared with ageâ€matched people from the general population. Haemophilia, 2018, 24, e6-e10.	2.1	15
174	Hemostatic defects in liver and renal dysfunction. Hematology American Society of Hematology Education Program, 2012, 2012, 168-73.	2.5	15
175	Charge heterogeneity of human protein C revealed by isoelectric focusing in immobilized pH gradients. Electrophoresis, 1985, 6, 373-376.	2.4	14
176	Factor VIII products in haemophilia A: one size fits all?. Thrombosis and Haemostasis, 2015, 113, 911-914.	3.4	14
177	Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. European Journal of Internal Medicine, 2015, 26, 243-249.	2.2	14
178	Risk factors for three-month mortality after discharge in a cohort of non-oncologic hospitalized elderly patients: Results from the REPOSI study. Archives of Gerontology and Geriatrics, 2018, 74, 169-173.	3.0	14
179	A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. Expert Review of Hematology, 2018, 11, 87-97.	2.2	14
180	Von Willebrand disease type 2N: An update. Journal of Thrombosis and Haemostasis, 2021, 19, 909-916.	3.8	14

#	Article	IF	Citations
181	Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfusion, 2013, 11, 533-40.	0.4	14
182	Use and prescription appropriateness of drugs for peptic ulcer and gastrooesophageal reflux disease in hospitalized older people. European Journal of Clinical Pharmacology, 2020, 76, 459-465.	1.9	13
183	Use of Prophylaxis to Prevent Complications of Hemophilia. Advances in Experimental Medicine and Biology, 2001, 489, 59-64.	1.6	13
184	Electroblot and Immunoperoxidase Staining for Rapid Screening of the Abnormalities of the Multimeric Structure of von Willebrand Factor in von Willebrandâ€™s Disease. Thrombosis and Haemostasis, 1986, 55, 246-249.	3.4	13
185	Gly319â€ƒâ†'â€ƒArg substitution in the dysfunctional prothrombin Segovia. British Journal of Haematology, 1999, 105, 667-669.	2.5	12
186	Need for randomized trials in hemophilia. Journal of Thrombosis and Haemostasis, 2006, 4, 501-502.	3.8	12
187	Desmopressin: an historical introduction. Haemophilia, 2008, 14, 1-4.	2.1	12
188	Thromboprophylaxis in the oldest old with atrial fibrillation: Between Scylla and Charybdis. European Journal of Internal Medicine, 2013, 24, 285-287.	2.2	12
189	Investigational drugs for coagulation disorders. Expert Opinion on Investigational Drugs, 2013, 22, 945-953.	4.1	12
190	Integrated postural analysis in children with haemophilia. Haemophilia, 2014, 20, 263-267.	2.1	12
191	The safety of pharmacologic options for the treatment of persons with hemophilia. Expert Opinion on Drug Safety, 2016, 15, 1391-1400.	2.4	12
192	Monoclonal Antibodies Directed to the Calcium-Free Conformation of Human Protein S. Thrombosis and Haemostasis, 1989, 62, 708-714.	3.4	12
193	The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Transfusion, 2013, 11 Suppl 4, s64-76.	0.4	12
194	The European standards of Haemophilia Centres. Blood Transfusion, 2014, 12 Suppl 3, s525-30.	0.4	12
195	von Willebrand disease in the 21st century: current approaches and new challenges. Haemophilia, 2009, 15, 1154-1158.	2.1	11
196	Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management. Haemophilia, 2013, 19, 344-348.	2.1	11
197	Haematology clinic: Haemophilia A. Hematology, 2014, 19, 181-182.	1.5	11
198	Editorial. Journal of Thrombosis and Haemostasis, 2006, 4, 1-2.	3.8	10

#	Article	IF	Citations
199	Fine particulate: it matters. Journal of Thrombosis and Haemostasis, 2010, 8, 659-661.	3.8	10
200	The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade. Haemophilia, 2012, 18, 2-7.	2.1	10
201	Pharmacist-driven medication recognition/ reconciliation in older medical patients. European Journal of Internal Medicine, 2021, 83, 39-44.	2.2	10
202	Sustainable and personalized nutrition: From earth health to public health. European Journal of Internal Medicine, 2021, 86, 12-16.	2.2	10
203	Impact of Diabetes Mellitus and Its Comorbidities on Elderly Patients Hospitalized in Internal Medicine Wards: Data from the RePoSi Registry. Healthcare (Switzerland), 2022, 10, 86.	2.0	10
204	Treatment of von Willebrand disease. Thrombosis and Haemostasis, 2001, 86, 149-53.	3.4	10
205	Autoimmune hemophilia at rescue. Haematologica, 2009, 94, 459-461.	3.5	9
206	Mechanism of hemostasis defects and management of bleeding in patients with acute coronary syndromes. European Journal of Internal Medicine, 2010, 21, 254-259.	2.2	9
207	Antipsychotic prescription and mortality in hospitalized older persons. Psychogeriatrics, 2017, 17, 397-405.	1.2	9
208	Consistency of ADAMTS-13 activity assays: a moderately optimistic view. Journal of Thrombosis and Haemostasis, 2003, 1, 1880-1881.	3.8	8
209	Thrombosis and bleeding disorders outside Western countries. Journal of Thrombosis and Haemostasis, 2007, 5, 68-72.	3.8	8
210	Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No. Journal of Thrombosis and Haemostasis, 2008, 6, 1450-1452.	3.8	8
211	Activated Partial Thromboplastin Time. Scandinavian Journal of Haematology, 2009, 25, 308-317.	0.0	8
212	Pediatric requirements in Europe stymie help for hemophilia. Nature Medicine, 2014, 20, 117-117.	30.7	8
213	Involvement of the IgEâ€basophil system and mild complement activation in haemophilia B with antiâ€factor IX neutralizing antibodies and anaphylaxis. Haemophilia, 2017, 23, e348-e353.	2.1	8
214	Viral safety of coagulation factor concentrates: memoirs from an insider. Journal of Thrombosis and Haemostasis, 2018, 16, 630-633.	3.8	8
215	Bleeding Disorders in Primary Fibrinolysis. International Journal of Molecular Sciences, 2021, 22, 7027.	4.1	8
216	Treatment of von Willebrand disease. International Journal of Clinical and Laboratory Research, 1998, 28, 211-214.	1.0	7

#	Article	IF	Citations
217	The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy. Internal and Emergency Medicine, 2015, 10, 305-313.	2.0	7
218	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with ageâ€matched controls. Haemophilia, 2018, 24, 726-732.	2.1	7
219	AGING WITH HEMOPHILIA: THE CHALLENGE OF APPROPRIATE DRUG PRESCRIPTION. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019056.	1.3	7
220	New therapies for von Willebrand disease. Hematology American Society of Hematology Education Program, 2019, 2019, 590-595.	2.5	7
221	Traffic-related air pollution and the coronavirus pandemia: shadows and lights. European Journal of Preventive Cardiology, 2022, 28, e3-e5.	1.8	7
222	Use of Lipid-Lowering Drugs and Associated Outcomes According to Health State Profiles in Hospitalized Older Patients. Clinical Interventions in Aging, 2021, Volume 16, 1251-1264.	2.9	7
223	Effects of Factor VIII Concentrates on the Immune System of Patients with Hemophilia. Thrombosis and Haemostasis, 1995, 74, 437-439.	3.4	7
224	B19 Parvovirus Withstands â€œSuper Heatingâ€•in Antihemophilic Concentrates. Thrombosis and Haemostasis, 1996, 76, 821-821.	3.4	7
225	Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors. Haemophilia, 2022, 28, 55-64.	2.1	7
226	The increased demand for plasma-derived factor VIII in Italy. Blood Transfusion, 2017, 15, 279-280.	0.4	7
227	Viral safety of plasma-derived and recombinant products used in the management of haemophilia A and B. Haemophilia, 1995, 1, 14-20.	2.1	6
228	The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. British Journal of Haematology, 2000, 111, 1223-1229.	2.5	6
229	Overview of Bleeding in Cancer Patients. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 44-45.	0.3	6
230	Predictors of clinical events occurring during hospital stay among elderly patients admitted to medical wards in Italy. European Journal of Internal Medicine, 2016, 32, 38-42.	2.2	6
231	Management of Hemophilia in Older Patients. Drugs and Aging, 2017, 34, 881-889.	2.7	6
232	Conflicts of interest in medicine: a never-ending story. Internal and Emergency Medicine, 2020, 15, 357-359.	2.0	6
233	Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry. Acta Diabetologica, 2021, 58, 1225-1236.	2.5	6
234	Integrated care: easy in theory, harder in practice?. Internal and Emergency Medicine, 2022, 17, 3-6.	2.0	6

#	Article	IF	Citations
235	Defensive medicine: Everything and its opposite. European Journal of Internal Medicine, 2020, 74, 117-118.	2.2	6
236	Choice of replacement therapy for hemophilia: recombinant products only?. The Hematology Journal, 2000, 1, 72-76.	1.4	6
237	Repeated Release of the Tissue Factor Pathway Inhibitor. Thrombosis and Haemostasis, 1994, 72, 327-328.	3.4	6
238	Transfusion Requirements Are Correlated with the Degree of Proteolysis of von Willebrand Factor during Orthotopic Liver Transplantation. Thrombosis and Haemostasis, 1997, 78, 813-819.	3.4	6
239	Characterization of an Abnormal Antithrombin (Milano 2) with Defective Thrombin Binding. Thrombosis and Haemostasis, 1986, 56, 349-352.	3.4	6
240	A certification/accreditation model for Haemophilia Centres in Italy. Blood Transfusion, 2014, 12 Suppl 3, s505-9.	0.4	6
241	Dissociated antibody responses to the s and pre-s2 regions of the hepatitis b virus after vaccination in hemophiliacs. Journal of Medical Virology, 1989, 28, 156-158.	5.0	5
242	The importance of ABO blood group in pharmacokinetic studies in haemophilia A. Haemophilia, 2018, 24, e122-e123.	2.1	5
243	Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis. Vascular Pharmacology, 2019, 113, 92-93.	2.1	5
244	Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study. Medical Principles and Practice, 2019, 28, 501-508.	2.4	5
245	Intelligent game engines for home exercises (exergames) in boys with haemophilia. Haemophilia, 2021, 27, e151-e154.	2.1	5
246	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment. Internal and Emergency Medicine, 2022, 17, 299-302.	2.0	5
247	Hemostatic Functions in Hypoalpha and Hyperbetalipoproteinemias. Thrombosis and Haemostasis, 1983, 50, 624-625.	3.4	5
248	Association between air temperature, air pollution and hospital admissions for pulmonary embolism and venous thrombosis in Italy. European Journal of Internal Medicine, 2021, , .	2.2	5
249	Cardiovascular health and ambient air pollution: lower is not enough. European Journal of Preventive Cardiology, 2022, 29, 1200-1201.	1.8	5
250	Prophylactic management of patients with von Willebrand disease. Therapeutic Advances in Hematology, 2021, 12, 204062072110640.	2.5	5
251	Histological and immunohistochemical findings in a fatal case of thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. Pathology Research and Practice, 2022, 231, 153796.	2.3	5
252	Pharmaceutical pricing in Europe: time to take the right direction. Internal and Emergency Medicine, 2022, 17, 945-948.	2.0	5

#	Article	IF	Citations
253	Emerging drugs for hemophilia B. Expert Opinion on Emerging Drugs, 2014, 19, 407-414.	2.4	4
254	Therapeutic Duplicates in a Cohort of Hospitalized Elderly Patients: Results from the REPOSI Study. Drugs and Aging, 2016, 33, 647-654.	2.7	4
255	Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa). Expert Opinion on Drug Safety, 2017, 16, 405-410.	2.4	4
256	Prognostic relevance of glomerular filtration rate estimation obtained through different equations in hospitalized elderly patients. European Journal of Internal Medicine, 2018, 54, 60-64.	2.2	4
257	Polypharmacy in older adults with severe haemophilia. Haemophilia, 2018, 24, e1-e3.	2.1	4
258	The dark age of Italian general practice research â€“ An Italian matter. European Journal of Internal Medicine, 2020, 73, 98-99.	2.2	4
259	Perspective â€“ The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. Blood Reviews, 2021, 50, 100849.	5.7	4
260	Combined Use of DNA Probes in First-Trimester Prenatal Diagnosis of Hemophilia A. Thrombosis and Haemostasis, 1987, 58, 988-992.	3.4	4
261	Frequency of Factor V Arg506 Gin in Italians. Thrombosis and Haemostasis, 1996, 75, 694-694.	3.4	4
262	Very Low Frequency of â€œNormandy Typeâ€•Mutations among Type 1 von Willebrand Disease Families. Thrombosis and Haemostasis, 1995, 73, 324-324.	3.4	4
263	Plasma-derived medicinal products: demand and clinical use. Blood Transfusion, 2013, 11 Suppl 4, s2-5.	0.4	4
264	Recombinant factor VIIa as haemostatic therapy in advanced liver disease. Blood Transfusion, 2013, 11, 487-90.	0.4	4
265	The methodology for defining the European standards for the certification of Haemophilia Centres in Europe. Blood Transfusion, 2014, 12 Suppl 3, s519-24.	0.4	4
266	Vaccine-induced immune thrombotic thrombocytopenia with atypical vein thrombosis: Implications for clinical practice. Phlebology, 2022, , 026835552110689.	1.2	4
267	Aspects of the Clinical Management of Hereditary Thrombophilia: A Personal Perspective. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2000, 30, 11-15.	0.3	3
268	Clinical governance: many fancies, very few facts. Internal and Emergency Medicine, 2012, 7, 3-4.	2.0	3
269	Reply to: The importance and challenge of pediatric trials of hemophilia drugs. Nature Medicine, 2014, 20, 466-466.	30.7	3
270	Recombinant porcine factor <scp>VIII</scp>: a new instalment of a long story. Haemophilia, 2015, 21, 149-151.	2.1	3

#	Article	IF	Citations
271	Reply to the letter by Iorio. Haemophilia, 2017, 23, e248-e249.	2.1	3
272	Community and hospital pharmacists in Europe: encroaching on medicine?. Internal and Emergency Medicine, 2021, 16, 7-10.	2.0	3
273	Risk of Inhibitor Development after Intermediate Purity Coagulation Factor Concentrates: Is It Truly Low?. Thrombosis and Haemostasis, 1995, 74, 997-997.	3.4	3
274	Thrombotic thrombocytopenic purpura: a simpler diagnosis at last?. Thrombosis and Haemostasis, 1999, 82, 1380-1.	3.4	3
275	Spontaneous platelet aggregation during pregnancy in a patient with von Willebrand disease type IIB can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa. British Journal of Haematology, 1990, 75, 86-91.	2.5	2
276	Homeopathy provided by a national health service: Only in Italy?. European Journal of Internal Medicine, 2017, 41, 1-2.	2.2	2
277	Use of desmopressin in the treatment of hemophilia A: towards a golden jubilee. Haematologica, 2018, 103, 379-381.	3.5	2
278	Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment. Internal and Emergency Medicine, 2022, 17, 303-306.	2.0	2
279	Thrombotic thrombocytopenic purpura and other immune-mediated blood disorders following vaccination against SARS-CoV-2. Haematologica, 2022, 107, 785-786.	3.5	2
280	Restriction of Polymerase Chain Reaction Products for Carrier. Thrombosis and Haemostasis, 1990, 63, 527-528.	3.4	2
281	Fibrin(ogen) Peptides in Early Breast Cancer. Thrombosis and Haemostasis, 1989, 62, 819.	3.4	2
282	Preliminary In Vivo Evaluation of a Nanofiltered Factor IX Concentrate. Thrombosis and Haemostasis, 1995, 73, 737-738.	3.4	2
283	Fibrinogens â€œMilano IIâ€• and â€œNaplesâ€• Thrombosis and Haemostasis, 1987, 57, 375-375.	3.4	2
284	Pharmaceutical patenting in the European Union: reform or riddance. Internal and Emergency Medicine, 2021, , 1.	2.0	2
285	Gene transfer in hemophilia A: not cogent yet. , 2022, 1, 7-8.		2
286	The knowledge and perception of factor concentrate in persons with haemophilia A. Haemophilia, 1995, 1, 232-235.	2.1	1
287	Partial inhibition of platelet aggregation by nebulized pentamidine in severe haemophiliacs. Haemophilia, 1997, 3, 31-34.	2.1	1
288	A novel two base pair deletion in the factor V gene associated with severe factor V deficiency. British Journal of Haematology, 2000, 111, 1240-1246.	2.5	1

#	Article	IF	Citations
289	Reply:. Hepatology, 2007, 45, 832-833.	7.3	1
290	William Hewson and the blood which issued last but clotted first: the beginning of the story of desmopressin in haemophilia and vWD. Haemophilia, 1996, 2, 180-183.	2.1	1
291	Aspirin as antiplatelet agent in diabetes: Cons. European Journal of Internal Medicine, 2010, 21, 154-156.	2.2	1
292	Getting rid of refractory hemophilia. Blood, 2012, 119, 1326-1327.	1.4	1
293	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. European Journal of Internal Medicine, 2014, 25, 847-852.	2.2	1
294	Appropriateness of antithrombotic prophylaxis in the oldest old with non-valvular atrial fibrillation: ARAPACIS and REPOSI. European Journal of Internal Medicine, 2015, 26, e47-e48.	2.2	1
295	More on air pollution and venous thromboembolism. European Journal of Internal Medicine, 2017, 37, e11.	2.2	1
296	Use of non-steroidal anti-inflammatory drugs and analgesics in a cohort of hospitalized elderly patients: Results from the REPOSI study. European Journal of Internal Medicine, 2017, 38, e11-e12.	2.2	1
297	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. Age and Ageing, 2021, 50, 498-504.	1.6	1
298	Authorsâ€™ Reply to Brunetti et al. â€œPotentially Inappropriate Medications, Drugâ€“Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes?â€• Drugs and Aging, 2021, 38, 93-94.	2.7	1
299	IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A. British Journal of Haematology, 2021, 192, 621-625.	2.5	1
300	Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A. Haemophilia, 2021, 27, e441-e449.	2.1	1
301	Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. Haemophilia, 2021, 27, e525-e529.	2.1	1
302	ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates. Blood, 2012, 120, 3383-3383.	1.4	1
303	Treatment of von Willebrand's disease. Journal of Internal Medicine Supplement, 1997, 740, 129-32.	0.0	1
304	EVALUATION OF A FULLY AUTOMATED CENTRIFUGAL ANALYSER FOR ITS PERFORMANCE OF HEMOSTASIS TESTS. , 1987, 58, 0457.		0
305	Antiplatelet Agents in Acute Myocardial Infarction and in the Post-infarction Period. Platelets, 1993, 4, 24-25.	2.3	0
306	Ilsley Ingram. Journal of Thrombosis and Haemostasis, 2004, 2, 1219-1219.	3.8	0

#	Article	IF	Citations
307	Thrombolytic therapy in acute myocardial infarction. Journal of Thrombosis and Haemostasis, 2005, 3, 2806-2807.	3.8	0
308	Making clinical decisions on the basis of RODIN. Haemophilia, 2014, 20, e174-e175.	2.1	0
309	Introduction and overview. Blood Reviews, 2015, 29, S1-S3.	5.7	0
310	How to win space in medical journals: Bits and tips. European Journal of Internal Medicine, 2018, 50, 1-2.	2.2	0
311	Witnessing the 1980s. Haemophilia, 2020, 26, 373-374.	2.1	0
312	What changed in the Italian internal medicine and geriatric wards during the lockdown. European Journal of Internal Medicine, 2021, 84, 97-100.	2.2	0
313	Localization and Function of Platelet ADAMTS-13.. Blood, 2005, 106, 3967-3967.	1.4	0
314	Non-Sense-Mediated mRNA Decay in ADAMTS13 Gene Caused by 29 Nucleotide Deletion.. Blood, 2006, 108, 1061-1061.	1.4	0
315	Understanding hemostasis and thrombosis : The lesson learnt from natural models. Japanese Journal of Thrombosis and Hemostasis, 2008, 19, 85-91.	0.1	0
316	Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.. Blood, 2009, 114, 3154-3154.	1.4	0
317	Haemophilia Centre Certification Systems: optional or optimal choice for healthcare systems?. Blood Transfusion, 2014, 12 Suppl 3, s492-4.	0.4	0
318	The search for the causes of myocardial infarction. Introduction. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2001, 2, 489.	0.1	0
319	Autoimmune bleeding disorders in cancer patients. Haemostasis, 2001, 31 Suppl 1, 45-6.	0.0	0
320	Managing prostatic illness in persons with haemophilia. Haemophilia, 2022, 28, 369-370.	2.1	0
321	Thrombotic thrombocytopenic purpura and other immune mediated blood disorders following SARS-CoV-2 vaccination. Haematologica, 2021, , .	3.5	0
322	An ecological alliance against air pollution and cardiovascular disease. , 2022, 1, 19-23.		0
323	Health technology assessment for pharmaceuticals in the European Union: what lessons after two decades?. Internal and Emergency Medicine, 0, , .	2.0	0